ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report

<p class="MsoNormal">In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy. </p> <p class="MsoNormal">  In this interview, Judith S. Hochman, MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report. </p> <p class="MsoNormal">  <a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046" target="_blank" rel="noopener">Subscribe on Apple</a> <u>Podcasts</u> | <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq" target="_blank" rel="noopener">Subscribe on Google Play</a> <u>|</u> <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio" target="_blank" rel="noopener">Subscribe to ACCEL</a> </p>